Pharmacovigilance Risk Assessment Committee makes recommendations to minimise risk of diabetic ketoacidosis (DKA) with SGLT2 inhibitors (e.g. canagliflozin, dapagliflozin or empagliflozin) -

Pharmacovigilance Risk Assessment Committee makes recommendations to minimise risk of diabetic ketoacidosis (DKA) with SGLT2 inhibitors (e.g. canagliflozin, dapagliflozin or empagliflozin)
Information type: Safety alerts
Source: European Medicines Agency
Specialities: Diabetes | Emergency medicine and urgent care | Paediatric and neonatal medicine
Summary
The PRAC has made recommendations similar to those in a recent MHRA Drug Safety Update. Additionally the PRAC recommends temporarily stopping SGLT2-inhibitor treatment in patients in hospital for major surgical procedures or due to serious illness.
UKMi comment
An recent Drug Safety Update from the MHRA recommends:

• Testing for raised ketones in patients with symptoms of DKA

• Stopping SGLT2 inhibitor treatment if DKA is suspected

• Take appropriate measures to correct the DKA and monitoring glucose levels if DKA is confirmed

• Informing patients of the symptoms and signs of DKA, and advising them to get immediate medical help if these occur

• Being aware that SGLT2 inhibitors are not approved for treatment of type 1 diabetes
Related links: Drug Safety Update